RecruitingNCT05511363
This study is recruiting in the United States, in France, in the United Kingdom, .... It is testing KarXT for Schizophrenia.
In United StatesSchizophreniaDrugA study involving a medication or substance.From 55 Years to 90 Years
- Countries
- United States, France, United Kingdom, ...
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
RecruitingNCT06126224
This study is recruiting in the United States, in Canada, in the United Kingdom, .... It is testing KarXT for Schizophrenia.
In United StatesSchizophreniaDrugFrom 55 Years to 90 Years
- Countries
- United States, Canada, United Kingdom, ...
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
RecruitingNCT06540833
This study is recruiting in the United States, in Bulgaria, in Croatia, .... It is testing ITI-1284 for Schizophrenia.
In United StatesSchizophreniaDrugOver 55 Years
- Countries
- United States, Bulgaria, Croatia, ...
- Sponsor
- Intra-Cellular Therapies, Inc.
- Condition
- Schizophrenia
RecruitingNCT06887192
This study is recruiting in the United States, in France, in Canada, .... It is testing ML-007C-MA for Schizophrenia.
In United StatesSchizophreniaDrugFrom 55 Years to 90 Years
- Countries
- United States, France, Canada, ...
- Sponsor
- MapLight Therapeutics
- Condition
- Schizophrenia
RecruitingNCT06524830
This study is recruiting in the United States, in Australia, in Canada, .... It is testing VLS-01 Buccal Film, Compared to Placebo for depression.
In United StatesDepressionDrugFrom 18 Years to 65 Years
- Countries
- United States, Australia, Canada, ...
- Sponsor
- atai Therapeutics, Inc.
- Condition
- Depression
RecruitingNCT06929273
This study is recruiting in the United States, in Australia, in France, .... It is testing KarXT for manic episodes in bipolarity type I.
In United StatesBipolarityDrugFrom 18 Years to 65 Years
- Countries
- United States, Australia, France, ...
- Sponsor
- Bristol-Myers Squibb
- Condition
- Bipolarity
RecruitingNCT06585787
This study is recruiting in the United States, in France, in Belgium, .... It is testing KarXT for Schizophrenia.
In United StatesSchizophreniaDrugFrom 55 Years to 90 Years
- Countries
- United States, France, Belgium, ...
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
RecruitingNCT07191483
This study is recruiting in the United States. It is testing KYN-5356 for schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Kynexis B.V.
- Condition
- Schizophrenia
RecruitingNCT06947941
This study is recruiting in the United States, in Australia, in Canada, .... It is testing Safety and Efficacy of KarXT + KarX-EC for Schizophrenia.
In United StatesSchizophreniaDrugFrom 55 Years to 90 Years
- Countries
- United States, Australia, Canada, ...
- Sponsor
- Bristol-Myers Squibb
- Condition
- Schizophrenia
RecruitingNCT07221877
This study is recruiting in the United States. It focuses on Schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Bristol-Myers Squibb
- Condition
- Schizophrenia
RecruitingNCT07610473
This study is recruiting in the United States. It is testing DT-101 for depression.
In United StatesDepressionDrugFrom 18 Years to 75 Years
- Countries
- United States
- Sponsor
- Draig Therapeutics Ltd
- Condition
- Depression
RecruitingNCT07300969
This study is recruiting in the United States, in the United Kingdom, in Bulgaria, .... It is testing DT-101 for depression.
In United StatesDepressionDrugFrom 18 Years to 75 Years
- Countries
- United States, United Kingdom, Bulgaria, ...
- Sponsor
- Draig Therapeutics Ltd
- Condition
- Depression
